RFK Jr. Faces Bipartisan Pushback at HHS FY2027 Budget Hearing

Why it matters: The Senate Appropriations Subcommittee on Labor, HHS, Education, and Related Agencies convened Tuesday, April 21, for an HHS FY2027 budget hearing that put Secretary Robert F. Kennedy Jr. on defense over a proposed $15.8 billion cut to the Department of Health and Human Services. The hearing's most striking tension came not from Democrats alone, but from the Republican chair herself, signaling the administration's budget faces a difficult road even among allies.

The big picture: The Trump administration's fiscal year 2027 budget proposes $111.1 billion for HHS, a 12.5 percent reduction from fiscal year 2026 enacted levels. The proposal includes more than $5 billion in cuts to the National Institutes of Health and the elimination of select programs at the National Institute for Occupational Safety and Health. Congress rejected a similar HHS reorganization proposal during the fiscal year 2026 appropriations process. Kennedy has now testified before at least five congressional panels in April alone, including the House Ways and Means Committee on April 16 and the House Energy and Commerce Health Subcommittee on the same day as this Senate hearing.

The April 21 Senate hearing is the latest in a two-week congressional accountability offensive that PBS NewsHour described as a "gauntlet." It comes as a measles outbreak has produced roughly 1,600 cases in the first quarter of 2026 alone, according to Salon, and one year after a sweeping round of DOGE-driven HHS workforce reductions that Healthcare Dive characterized as leaving the department "in disarray."

What they're saying:

  • Sen. Shelley Moore Capito (R-WV), the subcommittee chair: "I'm concerned that our science, our country, is falling behind in biomedical research."

  • Sen. Tammy Baldwin (D-WI), ranking member: "I expect Congress to reject this budget request, just like we did last year."

  • Kennedy, on NIH cuts: "I don't want to cut NIH programs, Russ Vought doesn't want to cut NIH programs, but we have a $35 trillion debt."

The atmosphere was pointed from the opening gavel. Baldwin's prediction that Congress would reject the request set a confrontational Democratic posture, while Capito's concerns about biomedical competitiveness undercut the administration's framing of the cuts as straightforward efficiency measures. Kennedy, at times visibly working to thread the needle between fiscal discipline and program defense, acknowledged the cuts were "painful" while attributing them to broader budgetary constraints rather than ideological intent.

Baldwin pressed Kennedy directly on the administration's rollback of the "press 3" option for LGBTQ+ youth on the national suicide hotline, noting that the fiscal year 2026 Labor-HHS appropriations law already requires HHS to restore it, according to Politico. Kennedy also faced questions about a contract awarded to David Geier, a figure associated with discredited vaccine-autism research, and committed to sharing contract details with senators by week's end, per U.S. News & World Report.

On mRNA vaccines, Kennedy fired back at members who cited peer-reviewed clinical trials, claiming mRNA technology "does not work for respiratory illnesses," a claim that contradicts published findings in the New England Journal of Medicine cited during the hearing.

Political stakes: Capito's public skepticism puts her in a bind. She co-authored a bipartisan fiscal year 2026 Labor-HHS bill with Baldwin, a track record that now creates expectations she will again push back on the administration's most aggressive cuts. Her explicit opposition to eliminating NIOSH programs, and her concern about falling behind in biomedical research, are early markers that the subcommittee will not simply rubber-stamp the White House's request. West Virginia's dependence on federal health infrastructure and Medicaid gives her both political cover and constituent pressure to negotiate modifications.

For Kennedy, the stakes are compounding. He faces Democratic attacks on vaccines, public health funding, and agency dysfunction, while CNN reported that the White House has been "discouraging Kennedy and his aides from publicly discussing their efforts to overhaul vaccine policies," suggesting he may be losing internal influence even as he defends the administration's agenda on Capitol Hill. His acknowledgment that roughly 20 percent of DOGE-driven cuts would need to be reversed due to errors further complicated his managerial credibility.

The other side: Kennedy argued that prior NIH spending was misdirected, telling the subcommittee that "a lot of the money was wasted," per Time. He also pointed to what he described as historic wins under his tenure, including drug price negotiations with pharmaceutical companies and new dietary guidelines that he said reoriented federal nutrition guidance toward whole foods. On drug pricing, Kennedy bristled at Democratic criticism, telling one senator: "Why don't you do an agreement yourself? You've had power to do that for 20 years and haven't done it," according to PBS NewsHour.

What's next: The subcommittee must now draft and mark up the fiscal year 2027 Labor-HHS appropriations bill, the primary legislative vehicle for translating hearing findings into law. The Geier contract disclosure deadline, set for this week, could generate a fresh round of oversight activity. The DOGE Temporary Organization is set to terminate on July 4, 2026, adding a structural deadline to ongoing questions about HHS reorganization authority. A parallel reconciliation process moving through Congress could also reshape Medicaid funding structures independent of the appropriations track.

The bottom line: Bipartisan resistance to the administration's HHS budget is real, and the Republican chair of the subcommittee that must write the bill has already drawn lines the White House will have to negotiate around.

Access the Legis1 platform for comprehensive political news, data, and insights.